Introduction
Radiotherapy has been extensively applied in cancer therapy except for surgery and chemotherapy. This technique employs high-energy X-rays and involves deposition of irradiation doses in tumor sites by causing free radical damage or DNA damage. [1] [2] [3] [4] However, poor radiosensitivity or inherent radioresistance of tumors leads to utilization of higher irradiation doses for effective elimination of cancer cells; this radioresistance is caused by various mechanisms (eg, hypoxic, S-phase) which may finally limit the clinical implementation of radiotherapy. Besides, inaccuracy of tumor localization and poor discrimination between lesion and tumor-surrounding tissues lead to inadequate dose coverage to the lesion tissues and overexposure to normal tissues, 5 which results in the occurrence of irradiation side effects and failure of tumor control as well as cancer recurrence. Therefore, development of a new effective way for enhancing tumor radiosensitivity while minimizing systemic side effects becomes an urgent strategy. In this aspect, combining chemotherapy and radiotherapy is a well-established technique for radiosensitization. The newly developed theranostic formulations offer several advantages including assessment of biodistribution and noninvasive accumulation of drugs at target sites, visualization of drug distribution and drug release at the target site, optimization of formulation which relies on triggered drug release, and real-time monitoring of the therapeutic responses with the help of different kinds of imaging modalities.
In recent years, nanotechnology has been considered as an attractive strategy for cancer diagnostics and therapy owing to its multifunctional applications in tumor-targeted drug delivery and drug localization. [7] [8] [9] [10] [11] [12] Additionally, nanoparticles (NPs) could be ideal candidates for accurate tumor-targeting imaging to locate tumors because of their prolonged circulation time, selective accumulation in tumors by the enhanced permeability and retention effect, and active targeting through conjugating with folic acid, antibodies, peptides, or hyaluronic acid (HA). 13 In addition, the X-ray dose of the surrounding tissue will be greatly reduced, and higher dose can be concentrated at the tumor region containing NPs. Interestingly, NPs were designed to serve as radiosensitization enhancers. [14] [15] [16] Heavy metal (with high-Z elements such as Au, Pt, Bi, Ta, Gd, and Lu 17, 18 ) NPs as promising computed tomography (CT) contrast agents (CAs) could be used in radiosensitizing therapy because of their high X-ray photon capture cross-section and compton scattering effect. When X-rays interact with high-Z NPs, Auger electrons and photoelectrons are emitted, with diameters ranging from nanometers to several micrometers. Furthermore, when photon beams of kilovolt and megavolt energy interact with high-Z NPs in a tumor, the release of secondary electrons can injure tumor cells, leading to a higher treatment efficacy than radiation alone.
CT is a mainstay of clinical diagnostic modality with the advantages of high resolution, no depth limitation, and possibility of three-dimensional reconstruction. However, pharmacokinetic limitations of clinically available CT CAs (small iodinated molecules), including short circulation half-lives and nonspecific distribution, are the main causes of CT failure for tumor-targeting imaging and angiography. Moreover, various intrinsic limitations of CT imaging particularly with respect to inadequate soft tissue contrast, low-throughput capacity, limited accessibility, and ionizing radiation are also considered as notable hurdles that prevent the application of CT for clinical diagnosis. 19 To date, bismuth-based NPs (BiNPs) such as Bi 2 S 3 nanodots [20] [21] [22] and Bi 2 Se 3 nanoplates 23 have been employed as CT CAs which are commonly used in clinical imaging. Moreover, BiNPs have received wide attention in the field of radiotherapy research due to their remarkable radiation dose enhancement under kilovolt-energy X-ray beams, which is significantly higher than the well-known gold radiation sensitizer. 24 As a direct thin-band-gap n-type semiconductor (1.3 eV), Bi 2 S 3 NPs with high near-infrared (NIR) absorption coefficient have been used as NIR absorbers to extend the absorption wavelength to the NIR region for the improvement of solar-harnessing capability of solar cells. [25] [26] [27] [28] Encouraged by the ideal NIR absorption property of BiNPs, it is very much possible to use them as CT agents, which thus makes them a simple but powerful precision nanomedicine that comprises only Bi 2 O 3 NPs without any additional functional components that can be used to simultaneously achieve CT bimodal imaging. However, it has been suggested that the significant radiosensitization effect of Bi 2 S 3 NPs could be successfully realized through their inhibition effect on tumor growth in a tumor-bearing mice model, where intrinsic potential biological toxicity of sulfur element could not be ignored. 29 Furthermore, as we have known, the lower cost of bismuth element and higher radiation dose enhancement 30, 31 compared to gold element could make the BiNP a better candidate for further commercial use. Thus, it is suggested that Bi 2 O 3 NP can be used as an ideal alternative to evaluate the therapeutic effect of nanomedicine-based radiosensitizers in the interstitial radiotherapy research.
HA is a naturally linear polysaccharide and a major ligand due to its biocompatible, nontoxic, biodegradable, and non-immunogenic advantages. As a target-specific drug delivery carrier, HA has been investigated well in the HA receptor-mediated endocytosis because of its polyanionic characteristics and hydrophilicity, 32 and highly efficient targeted delivery to target sites with HA receptors, such as CD44, HARE, and LYVE-1, for various biological functions. 33, 34 According to over-mentioned intensive reports, we chose HA as a targeting ligand to synthesize the HA-Bi 2 O 3 NPs as a multifunctional theranostic platform that can afford spatialand temporal-specific CT imaging and enable overcoming cancer radioresistance. This specifically developed tumortargeted probe holds a great promise as a CT imaging CA with better CT imaging quality at reduced CA dosage when compared with the currently available CAs imaged using a clinical CT scanner. In order to exploit the attractive features of Bi element and that of multifunctional NPs, we evaluated the radiosensitizing effect of HA-Bi 2 O 3 NPs in hepatoma cells in vitro and tumor-bearing female mice model in vivo.
Materials and methods Materials
Fluorescein diacetate (FDA) and propidium iodide (PI) were purchased from Sigma (St Louis, MO, USA). BiCl 3 ⋅6H 2 O and diethylene glycol (99%) were acquired from Hengrui Pharmaceutical Co., Ltd (Lianyungang, People's Republic of China). 3-(4,5-Dimethyl-thiazol-2-yl)-5-(3-carbo xymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) was purchased from Promega (Cell Titer Aqueous One Solution Cell Proliferation Assay kit; Madison, WI, USA). The HA-Bi 2 O 3 NPs were prepared using a slightly modified procedure of the "polyol" method developed by Petoral et al. 35 Specifically, 5.7 mmol BiCl 3 was dissolved in 30 mL of diethylene glycol (DEG) and constantly stirred to form a transparent viscous solution. The solution was heated in a silicon oil bath at 140°C-160°C for 1 h. Then, 7.5 mmol NaOH dissolved in 30 mL of DEG was added. After complete dissolution of the reactants, the solution was refluxed at 180°C for 30 min under vigorous stirring. The prepared NPs were cooled to room temperature. Subsequently, 0.5 mmol HA and 0.5 mmol NaOH were added. The solution was then refluxed at room temperature for 6 h under strong stirring, yielding a white precipitate. After the system was cooled to room temperature naturally, the transparent suspension was filtered with a 0.22-μm membrane to remove any large-sized agglomerates. The prepared solution was then dialyzed against water for 3 days in a 14-kDa molecular weight cutoff dialysis bag. The dialysis solution was collected and freeze-dried using a vacuum freeze dryer. Thus, HA-Bi 2 O 3 NPs powders were obtained and stored for further characterization.
Instrumentation and characterizations
The chemical structures of HA-Bi 2 O 3 NPs were analyzed using a Fourier transform infrared (FT-IR) spectrometer (Nicolet Nexus 470; GMI, Franklin, IN, USA). The elemental composition was determined by elemental analysis performed using X-ray photoelectron spectroscopy (XPS). The resultant particle sizes were analyzed by a NanoDLS particle size analyzer (Brookhaven Instruments Corporation, Holtsville, NY, USA). The morphologies of the HA-Bi 2 O 3 NPs were examined by high-resolution transmission electron microscopy (HRTEM) on a JEM-2100 microscope (JEOL, Tokyo, Japan) under an accelerating voltage of 200 kV. Ultravioletvisible (UV-Vis) absorption spectra were recorded using a UV-2450 UV-Vis spectrophotometer (Shimadzu, Kyoto, Japan). Photoluminescence emission measurement was made using a Cary Eclipse Fluorometer (Varian, Palo Alto, CA, USA). The bismuth element of HA-Bi 2 O 3 NPs was quantified by linear calibration using amounts of potassium iodine previously determined by inductively coupled plasma mass spectroscopy (ICP-MS). 36 and incubated for 24 h at 37°C and 5% CO 2 , and then the growth medium was replaced with DMEM containing different concentrations of HA-Bi 2 O 3 NPs. Each sample was prepared in triplicate. After incubation for 24 h, 20 μL MTS solution was added to each well and incubated for 3 h at 37°C under 5% CO 2 . The absorbance of each well was measured at 490 nm using Synergy HT Multi-Mode Microplate Reader (BioTek, Winooski, VT, USA). Non-seeded wells (containing only DMEM) were used as zero sitting, non-treated cells (in DMEM) were used as control, and the relative cell viability (mean ± SD, n=3) was expressed as (Abs sample − Abs zero sitting)/(Abs control − Abs zero sitting) ×100%.
cellular binding and uptake tests

hemolysis assay
All animal experiments in this study were executed according to the protocol approved by the 
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Du et al the literature [37] [38] [39] with slight modification. In brief, fresh mouse blood stabilized with heparin sodium was kindly prepared. The blood was centrifuged (1,200 rpm, 15 min) to remove supernatant, washed with PBS five times to completely remove serum, and obtain the mouse red blood cells (MRBCs). Thereafter, the diluted MRBC suspension (0.1 mL) was transferred into 2 mL tubes prefilled with 0.9 mL ddH 2 O (as positive control), 0.9 mL PBS (as negative control), and 0.9 mL PBS containing HA-Bi 2 O 3 NPs with different particle concentrations (25-800 μg/mL), respectively. The mixtures were incubated for 2 h at 37°C after gentle shaking and centrifuged at 12,000 rpm for 1 min. Finally, the photographs of the samples were taken, and the absorbance of the supernatants (hemoglobin) was measured by a UV-2450 UV-Vis spectrophotometer. The hemolysis percentages of different samples were calculated by dividing the difference in absorbance at 541 nm.
histological analysis
Mice were sacrificed 30 days after intravenous injection of HA-Bi 2 O 3 NPs at a dose of 40 mg/kg, and mice without the injection of HA-Bi 2 O 3 NPs were used as control. Susceptible tissues (heart, spleen, liver, lung, and kidney) were harvested from the above two groups (control and test groups). The organs were immersed in 4% paraformaldehyde for 24 h at 4°C, dehydrated, and treated for inclusion in paraffin. The specimen was sectioned serially at 4-mm thickness, stained with hematoxylin and eosin, and observed under an optical microscope.
Biodistribution of ha-Bi 2 O 3 NPs in vivo
To study the biodistribution of HA-Bi 2 O 3 NPs in vivo, the HA-Bi 2 O 3 NPs solution (40 mg/kg) in PBS was injected into ICR mice via the tail vein. After 24 h postadministration, mice were sacrificed, and organs were dissected and weighed. For ICP-MS assay, each sample was added to 5 mL of H 2 NO 3 , transferred to flasks, and sealed for predigestion overnight. Then, 3 mL of 30% H 2 O 2 was added to each flask. The flasks were heated at 120°C for 2 h and then cooled to room temperature. A series of Bi + standard solutions (0, 0.5, 1.5, 10, 50, and 100 ppb) were prepared with the above solution. Both standard and test solutions were measured by ICP-MS. The amount of Bi elements was finally normalized to the cell number or tissue weight per gram.
Live-dead staining assay and flow cytometry
To study the radiosensitization effect of HA-Bi 2 O 3 NPs, SMMC-7721 cells were seeded in six-well plates at a density of 4.0×10 4 cells/well and allowed to grow for 12 h and divided into six groups (control, HA-Bi 2 O 3 NPs, radiation, radiation +50 μg/mL HA-Bi 2 O 3 NPs, radiation +100 μg/mL HA-Bi 2 O 3 NPs, and radiation +200 μg/mL HA-Bi 2 O 3 NPs). When cells had grown to 80% in plates, the first group received no treatment, the second one was incubated with 200 μg/mL HA-Bi 2 O 3 NPs for 24 h, the third one was just irradiated at 6 Gy, and the fourth to sixth ones were irradiated at 6 Gy, and at the same time, incubated with different concentrations of HA-Bi 2 O 3 NPs (50, 100, and 200 μg/mL) for 24 h, respectively. After that, FDA and PI working buffer was added for cell staining. The fluorescence of stained cells was observed under a fluorescence microscope; live cells showed green color, and dead ones exhibited red color. Furthermore, cells treated by different treatments were washed three times with PBS, digested, collected, and centrifuged at a speed of 2,000 rpm for 5 min, and then fixed with 70% ethanol at −20°C overnight followed by PI staining. DNA fragmentation was quantified by the fluorescence intensity of PI on a Beckman Coulter Epics XL MCL flow cytometer (BD Accuri C6) and analyzed by software (Flowjo 7.6.2) to clearly understand the cell cycle distribution and apoptosis.
clonogenic survival assays
Cells were seeded in six-well plates at a density of 1.0×10 3 cells/ well and permitted to grow for 16 h. The cells were incubated with 200 μg/mL HA-Bi 2 O 3 NPs diluted in cell culture medium for 6 h. The cells were then irradiated at 6 Gy. After irradiation, cells were allowed to grow for 14 days, fixed with 4% paraformaldehyde at room temperature for 40 min, and stained with 1% crystal violet after washing the cells. Cells were treated on a clinical linear accelerator (Oncor, Dallas, TX, USA) with 6 MV irradiation under a radiation field of 10×10 cm at a source-toskin distance (SSD) of 100 cm to cover the entire cells.
In vivo and in vitro cT imaging study and biodistribution of ha-Bi 2 O 3 NPs
In vitro and in vivo CT images were acquired on a clinical 64-slice multidetector CT scanner (SOMATOM Emotion; Siemens, Munich, Germany). To study the CT images in vitro, the solutions of HA-Bi 2 O 3 NPs with different concentrations ranging from 0 to 10 mg/mL were added to a 96-well culture plate, using the commercial contrast Omnipaque (GE Healthcare (Shanghai) Co., Ltd., Shanghai, People's Republic of China) as control. The X-ray attenuation intensity was evaluated with the average values of gray density by the corresponding software (ImageJ) and medical image analysis system. For CT imaging in vivo, we choose the normal ICR mice as model. The technology of establishing the animal models with Herps cells is very mature. 40 Animal models were established by the following procedures: First, 1×10 6 Herps cells were inoculated into mice intraperitoneally, and the ascites were collected after 5 days. Then, these ascites were injected subcutaneously at an SSD of 100 cm. When the tumor sizes reached ~100 mm 3 , subcutaneous tumors models were established and applied to the following experiments. To establish in situ tumor model, the tumor-bearing mice were sacrificed, and subcutaneously, tumors were dissected out. These solid tumors were cut into small pieces and inoculated into normal mice liver in situ. Five days post-inoculation, in situ tumor models were established. Mice bearing subcutaneous tumors were treated with radiation at 3 Gy per fraction at a total dose of 30 Gy within 10 days. The radiotherapy was conducted after 3 h of intravenous injection of HA-Bi 2 O 3 NPs (10 mg/kg), on a Siemens Primus clinical linear accelerator (6 MeV) using a radiation field of 10×10 cm to cover the entire tumor. Tumor growth and mouse weight were measured in the following days. The tumor sizes were measured by a caliper and calculated as follows: V = ab 2 /2, where V (mm 3 ) is the volume of the tumor, and a (mm) and b (mm) are the tumor length and tumor width, respectively. Relative tumor volumes were normalized to their initial sizes. Each group contained eight mice and statistical analysis was performed using Student's two-tailed t-test (P,0.05, P,0.001).
Results and discussion Preparation and characterization of ha-Bi 2 O 3 NPs
The HA-Bi 2 O 3 NPs were successfully fabricated according to the illustrated diagram in Figure 1 . In this study, the morphological examination was carried out by TEM, and the resultant particle sizes were analyzed by NanoDLS particle size analyzer. As shown in Figure 2A Compared to normal tissues, capillary endothelial permeability of tumor tissues was increased, and the endothelial gap was between 100 and 600 nm. 41 Therefore, NPs with desirable size are beneficial to accumulate in the tumor tissues and dramatically improve the passive targeting drug delivery efficiency. hydrophilicity and dispersibility in water. 42 The survey XPS spectrum ( Figure 3A) showed three typical peaks at 159.75, 285.1, and 532.65 eV, which indicated that the HA-Bi 2 O 3 NPs were mainly composed of bismuth, carbon, and oxygen elements. The high-resolution spectrum of Bi 5d ( Figure 3B ) revealed the presence of three strong peaks at 158.8, 159.2, and 160.0 eV with a spin-orbit splitting of 32 eV corresponding, respectively, to the Bi 2 O 3 , native oxide (Ntv Ox), and 
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Du et al 1s energy levels of Bi. These observations were in good agreement with previous reports for Bi 2 O 3 NPs. 43 The C (1s) spectrum as shown in Figure 3C was dominated by four major peaks positioned at 285.0, 285.4, 287.8, and 531.8 eV, which corresponded, respectively, to the 1s, C-OR, C=O, and COO-R energy levels of C atom. The O (1s) spectrum as shown in Figure 3D was dominated by two major peaks positioned at 530.5 and 531.8 eV, which corresponded to the bond between O (NaOH) and O (1s).
The crystal structure of the HA-Bi 2 O 3 NPs was investigated by X-ray diffraction. As shown in Figure 2D, 
X-ray attenuation capacity of the ha-Bi 2 O 3 NPs
We then investigated the X-ray attenuation capacity of the HA-Bi 2 O 3 NPs compared with the Omnipaque (commercial CT CAs). As shown in Figure 3E , the CT image brightness increased with the HA-Bi 2 O 3 NPs concentration, which was similar to the behavior of the Omnipaque solution. At the HA-Bi 2 O 3 NP concentration of 156.25 to 1×10 4 μg/mL, the mean gray values were 137.3 (156.25 μg/mL), 167.6 (312.5 μg/mL), 173.5 (625 μg/mL), 178.1 (1.25×10 4 μg/mL), 185.1 (2.5×10 3 μg/mL), and 199.1 (1×10 4 μg/mL); at the Omnipaque concentration of 156.25 to 1×10 4 μg/mL, the mean gray values were 114.1 (156.25 μg/mL), 127.9 (312.5 μg/mL), 149.5 (625 μg/mL), 156.9 (1.25×10 4 μg/mL), 164.0 (2.5×10 3 μg/mL), and 173.7 (1×10 4 μg/mL). The CT image of HA-Bi 2 O 3 NPs was much brighter than that of Omnipaque under the same dosage of radiation. Further quantitative analysis data showed that X-ray attenuation intensity of both HA-Bi 2 O 3 NPs and the Omnipaque increased with the mass concentration of radiodense element. Nevertheless, the HA-Bi 2 O 3 NPs exhibited much higher X-ray attenuation capacity than Omnipaque under the same radioactive element concentrations (156.25 μg/mL). The superior X-ray attenuation performance endowed HA-Bi 2 O 3 with ideal CT imaging capacity for identifying accurate localization of tumor tissue.
cellular binding and phagocytosis tests
The HA-Bi 2 O 3 NPs uptaken by cells were quantitatively evaluated using flow cytometry method. Cells were incubated with 100 μg/mL of the HA-Bi 2 O 3 NPs for 6 h. Ten thousand cells were collected and analyzed by flow cytometry (Figure 4A and B) . The single-color histograms indicated that the number of cells labeled by FITC-modified HABi 2 O 3 NPs was 97.66% (SMMC-7721) and 86.64% (MCF7), respectively. The results validated that HA-Bi 2 O 3 NPs were readily internalized by cancer cells.
In order to verify the HA receptor-mediated cellular uptake behavior, SMMC-7721 (CD44 high-expression cell line) and MCF7 cells (CD44 low-expression cell line) were pretreated with free HA before incubation with HA-Bi 2 O 3 NPs. As previously reported, [44] [45] [46] relative expression of CD44 in SMMC-7721 was higher than in MCF7 according to realtime PCR results; relative expression of CD44 in MCF7 was only 25.6% of the expression in SMMC-7721 ( Figure S3 ). From flow cytometry assay, it was found that the amount of HA-Bi 2 O 3 uptaken by SMMC-7721 cells (93.94%) was more than that of MCF7 cells (85.90%) (Figure 4C and D) . As expected, the uptake of HA-Bi 2 O 3 NPs was reduced to 68.19% in SMMC-7721 cells, but a slight change (75.88%) in MCF7 cells was observed when the two cell lines were pretreated simultaneously with free HA. Free HA was able to bind to CD44 and inhibited the binding of HA-Bi 2 O 3 to CD44 competitively; the influence of free HA on SMMC-7721 was noticeable because relative expression of CD44 in SMMC-7721 cells was higher than in MCF7 cells. These results suggest that HA-Bi 2 O 3 NPs could be effectively taken up through the HA receptor-mediated endocytosis. It was also worthy of note that SMMC-7721 cells exhibited much higher uptake of HA-Bi 2 O 3 NPs than MCF7 cells, implying the synergistic effect of CD44 on cellular internalization of HA-Bi 2 O 3 NPs.
In addition, we further employed confocal laser scanning microscopy to observe the intracellular distribution of FITClabeled HA-Bi 2 O 3 NPs in SMMC-7721 and MCF7 cells stained with LysoTracker Red DND-26 probe. Figure 4E shows that HA-Bi 2 O 3 NPs with green fluorescence exhibited a colocalization in the lysosomes with red fluorescence. Based on the data, we could speculate that HA-Bi 2 O 3 NPs may be preferably internalized into the lysosomes after receptor-mediated endocytosis. More importantly, the green fluorescence was more noticeable in SMMC-7721 than in MCF7. Because free Figure 5A , all the HA-Bi 2 O 3 NPs at different concentrations exhibited negligible cytotoxicity. Even at the concentration of 400 μg/mL and with 24-h exposure time, the cell viability was ~90%. Second, the hemocompatibility of the HA-Bi 2 O 3 NPs in vitro was estimated using hemolysis assay. As shown in Figures 5B and S4 , we obviously found the hemolysis of red blood cells in the positive control. On the contrary, no obvious hemolysis phenomenon was observed after incubation with different concentrations from 12.5 to 400 μg/ mL for 2 hours administration, which was similar to the negative normal saline. Compared to the negative control, the percentage of hemolysis at different concentration of HA-Bi 2 O 3 NPs was quantitatively evaluated based on the absorbance the supernatant at 541 nm. The results showed that the hemolysis percentages of the HA-Bi 2 O 3 NPs were all less than 7% in the studied concentration range from 25 to 800 μg/mL, which verified their favorable hemocompatibility. These results clearly indicated that the assynthesized HA-Bi 2 O 3 NPs had very low cytotoxicity and good hemobiocompatibility.
Biodistribution and histocompatibility of the ha-Bi 2 O 3 NPs in vivo
To further investigate whether HA-Bi 2 O 3 NPs could induce adverse effects (such as tissue damage, inflammation, or lesions) in the long term postinjection, we carried out a histological assessment of the susceptible organs of the mice (liver, heart, spleen, lung, and kidney) 30 days postadministration. As shown in Figure 5C , no obvious adverse effect associated with the administration of the HA-Bi 2 O 3 NPs was observed compared with the control group. The ICP-MS ( Figure S5 ) results reported that the HA-Bi 2 O 3 NPs presented more appreciable accumulation in the liver (27.80 μg/g) than in the heart (4.83 μg/g), lung (2.10 μg/g), spleen (6.17 μg/g), and kidney (7.40 μg/g). However, the in vivo toxicity assessment profiles confirmed that the liver was unaffected by the accumulation of HA-Bi 2 O 3 NPs at least in the long term. These preliminary results proved that HABi 2 O 3 NPs at the given dose hardly caused in vivo toxicity effects in the long term post-administration.
Tumor-targeted cT imaging
The possibility of using HA-Bi 2 O 3 NPs as CAs for CT imaging in vivo was studied using Cancer Research mice (ICR mice) as a model ( Figure S6 ). After intravenous injection of HA-Bi 2 O 3 NPs at a dose of 20 mg/kg, the CT images were acquired through different scan times. Figure 5A and B shows that HA-Bi 2 O 3 NPs exhibited gradual increases of CT signal intensities in tumor within 10 min. Compared with preinjection, a great contrast enhancement in tumor was observed clearly, indicating that HA-Bi 2 O 3 NPs caused a time-dependent increase of signals and exhibited a strong CT imaging capability at 10 min postinjection. Figure 6A and B also shows that the signal in both the kidney and bladder strongly increased at 30 min postinjection, which indicated the effective clearance of HA-Bi 2 O 3 NPs from the body via renal metabolism. These results were further confirmed through CT transverse scans at different levels.
radiosensitization of ha-Bi 2 O 3 NPs in vitro
Previous studies have demonstrated that heavy metal-based radiosensitizers could absorb high-energy photons and emit secondary electrons and Auger electrons, which trigger a series of biological and chemical effects, such as destruction of DNA, proteins, and other intracellular components. 47, 48 The therapeutic effectiveness of radiotherapy could not be realized completely due to inaccurate localization and inherent radioresistance of tumors. To address these limits, the excellent performance of HA-Bi 2 O 3 NPs as CAs in vitro has encouraged us to perform an in vivo experiment to investigate whether its potential could be applied to improve spatial localization accuracy for X-ray CT in radiosensitization of tumors. Firstly, cell counting kit-6 (cck8) assay was conducted to explore whether any dose enhancement was caused by this combination treatment. As depicted in Figure 7A , HABi 2 O 3 NPs-only (concentration ranging from 0 to 400 μg/mL) treatment had no significant influence on the SMMC-7721 cell viability, and X-ray (ranging from 0 to 9 Gy) irradiation treatment decreased the SMMC-7721 cell viability to 45% at 9 Gy. Especially, the combination of X-ray irradiation with HA-Bi 2 O 3 NPs dramatically decreased the SMMC-7721 cell viability to ,25% with the concentration of 200 μg/mL at 6 Gy. Next, clonogenic assay in SMMC-7721 cells was conducted to evaluate the change in cell viability caused by the combination treatment of X-ray irradiation and HA-Bi 2 O 3 
Mechanism of radiosensitization enhancement
Flow cytometry assay and live-dead staining assay were used to further research the radiosensitization mechanism by which the combination treatment of HA-Bi 2 O 3 NPs and X-ray radiation caused cell death. As shown in Figure 7C 
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ha-Bi 2 O 3 NPs for cT imaging-guided radiotherapy rate was 5.89%. When the concentration was 200 μg/mL, after radiation, the early apoptosis rate of cells was 41.2%, while the late apoptosis/necrosis rate reached 14.1%. As analyzed by flow cytometry (Figures 9A and S8 ), radiation (6 Gy) alone slightly caused 19.87% of G2/M phase arrest, which might induce apoptosis of cells. 49, 50 In addition, HABi 2 O 3 NPs (from 0 to 200 μg/mL) activated apoptotic cell death from 0.446% to 2.34%, as reflected by the sub-G1 proportions. 51 However, the combination of HA-Bi 2 O 3 NPs and radiation dose-dependently increased the extent of G2/M phase arrest and cell apoptosis. For instance, combination of HA-Bi 2 O 3 NPs (200 μg/mL) and radiation at 6 Gy enhanced the proportions of G2/M phase arrest and sub-G1 peak to 33% and 21.59%, respectively, which indicated that HA-Bi 2 O 3 NPs could be an efficient alternative to improve radiosensitization enhancements for radiotherapy and have great promising applications in radiotherapy of tumors.
Generally, the combination of HA-Bi 2 O 3 NPs and X-ray irradiation exhibited a synergistic effect on the decline of cell colony formation and the cell viability in a dose-dependent manner; radiosensitization enhancement effect on the basis of flow cytometry and live-dead staining corroborated that HA-Bi 2 O 3 NPs could be an efficient alternative to improve radiosensitization enhancement for radiotherapy. The flow cytometry data revealed that cells upon X-ray irradiation treatment assisted by HA-Bi 2 O 3 NPs showed irreversible damage, and the cells could no longer function or recover from the damage.
radiosensitization of ha-Bi 2 O 3 NPs in vivo
To specifically examine whether the therapeutic effects of HA-Bi 2 O 3 NPs can enable overcoming the inherent radioresistance of cancer cells in vivo, ICR mice bearing 100-mm 3 subcutaneous Herps flank tumors were divided into four groups (n=6 per group). Notably, contrast enhancement was visible within the tumors of mice that received HA-Bi 2 O 3 NPs, which enabled CT-guided stereoscopic radiation ( Figure S9 ). The tumor volumes of each group were measured and plotted as a function of time ( Figures 9B and S10) . The control group (PBS) and the group that received HA-Bi 2 O 3 NPs alone exhibited 2.5-to 3.0-fold increases in tumor volumes, respectively, compared to their original volumes, indicating that the HA-Bi 2 O 3 NPs had no influence on the tumor growth. The group that received HA-Bi 2 O 3 NPs without radiation also exhibited similar tumor growth as control group, indicating that HA-Bi 2 O 3 NPs are nontoxic without irradiation. Most importantly, HA-Bi 2 O 3 NPs exhibited significant damage on the tumors upon radiation, which quickly gave rise to tumor necrosis 2 days postinjection and subsequent complete tumor ablation without any regrowth during 10 days postinjection, which accords with the enhanced in vitro cytotoxicity. However, the control group that received only radiation exhibited tumor regrowth 3 days postinjection, and finally increase in tumor volumes during 4-10 days postinjection. The survival time 52 ( Figure 9C ) was measured from the time of injecting ascites subcutaneously at SSD. Mice that received HA-Bi 2 O 3 NPs prior to radiation therapy exhibited a statistically significant (P,0.05) improvement in median survival (35 days), compared to mice treated with radiation alone (24 days). Obviously, the group treated with HA-Bi 2 O 3 NPs exhibited more significant damage, which may be ascribed to their absorbing high-energy photons and emission of secondary electrons and Auger electrons. Moreover, deep penetration and uniform distribution of HA-Bi 2 O 3 NPs in tumor could also facilitate complete tumor destruction, contributing to eradication of residual cancer cells.
Conclusion
In summary, we developed bifunctional 
International Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peerreviewed journal focusing on the application of nanotechnology in diagnostics, therapeutics, and drug delivery systems throughout the biomedical field. This journal is indexed on PubMed Central, MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, Journal Citation Reports/Science Edition, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/ testimonials.php to read real quotes from published authors. Figure S9 self-prepared device for mice radiotherapy. Note: The mice were placed in a leaden device which exposed parts of the subcutaneous tumor to radiation treatment. Abbreviation: ra, radiation.
International
